Izotropic Announces Debt Settlement

Rhea-AI Summary

Izotropic (OTCQB: IZOZF) announced a debt settlement on April 21, 2026, settling $100,000 of a promissory note by issuing 500,000 Units at a deemed price of $0.20 per Unit.

Each Unit comprises one common share and one three‑year warrant exercisable at $0.20. All securities will be subject to a statutory hold period of four months and one day. Completion is subject to Canadian Securities Exchange approval.

Positive

• Debt principal reduced by $100,000
• Settlement avoids immediate cash outflow via security issuance
• Issuance priced at $0.20 per Unit

Negative

• Potential dilution of up to 1,000,000 shares if warrants exercised
• Settlement completion subject to Canadian Securities Exchange approval
• Issued securities subject to a 4 months + 1 day hold period

News Market Reaction – IZOZF

+15.06%

1 alert

+15.06% News Effect

On the day this news was published, IZOZF gained 15.06%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 21, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Lender") to settle a portion of the principal balance pursuant to a promissory note originally issued by the Company.

The Company previously entered into a promissory note dated April 1, 2022, with the Lender in the principal amount of $2,000,000 (the "Promissory Note").

Pursuant to the Agreement, the Company will settle $100,000 of the principal balance through the issuance of 500,000 units (each, a "Unit") at a deemed price of $0.20 per Unit, in full settlement of the portion of the principal balance. Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder to acquire one additional Share (each, a "Warrant Share") at a price of $0.20 per Warrant Share for a period of three (3) years from the date of issuance.

All securities to be issued in connection with the Interest Settlement will be subject to a statutory hold period of four (4) months and one (1) day, in accordance with applicable securities laws.

Completion of the Interest Settlement remains subject to the approval of the Canadian Securities Exchange.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293628

FAQ

What did Izotropic (IZOZF) announce on April 21, 2026 about its debt?

They will settle $100,000 of promissory debt by issuing 500,000 Units at $0.20 each. According to the company, each Unit includes one share and one warrant exercisable at $0.20 for three years, subject to a statutory hold period and exchange approval.

How many shares and warrants will Izotropic (IZOZF) issue in the April 21, 2026 settlement?

Izotropic will issue 500,000 Units, each consisting of one share and one warrant, totaling 500,000 shares and 500,000 warrants. According to the company, warrants are exercisable for one share at $0.20 per warrant share for three years.

What is the warrant exercise price and term in Izotropic's (IZOZF) April 21, 2026 agreement?

Warrants issued in the settlement have an exercise price of $0.20 and a three‑year term. According to the company, each warrant entitles the holder to acquire one additional share for three years from issuance.

Will Izotropic (IZOZF) need regulatory approval to complete the April 21, 2026 debt settlement?

Yes, completion of the settlement is subject to approval by the Canadian Securities Exchange. According to the company, the issuance also carries a statutory hold period of four months and one day under applicable securities laws.

How might Izotropic's (IZOZF) April 21, 2026 settlement affect shareholders?

Shareholders face potential dilution if warrants are exercised, representing up to 1,000,000 additional shares total. According to the company, the action reduces debt by $100,000 while creating warrants exercisable at $0.20 for three years.